ALLMedicine™ Hypopituitarism Center
Research & Reviews 757 results
https://emedicine.medscape.com/article/2089246-print
May 13th, 2022 - The reference range of urinary 17-ketosteroids is as follows[1] : Males: 10-20 mg (34-69 µmol)/24 h Females: 5-15 mg (17-52 µmol)/24 h Increases in levels of 24-hour urinary 17-ketosteroids are associated with the following: Adrenal tumors Cushing...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040214
BMC Endocrine Disorders; Yamada H, Washino S et. al.
Apr 27th, 2022 - This study aimed to evaluate whether hypereosinophilia is a clinical biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma treated with nivolumab plus ipilimumab. This was a retrospective cohort stu...
https://doi.org/10.1007/s11060-022-04007-6 10.1002/cncr.20412 10.1111/cen.14127 10.1210/jc.2005-2552 10.1186/1748-717X-5-109 10.1007/s11060-013-1262-8 10.1093/neuonc/noz225 10.1080/07435800.2017.1323913 10.3171/2018.5.JNS18509 10.2165/00019053-200017060-00008 10.1016/S0140-6736(00)04006-X 10.3171/2019.1.JNS182296 10.1016/S0140-6736(07)61602-X 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 10.3171/2011.2.JNS10566 10.1007/s00701-003-0174-3 10.1227/01.neu.0000371145.97148.e5 10.1007/s12020-021-02701-5 10.1016/j.ghir.2004.03.038 10.1038/ncpendmet1051 10.1016/j.jns.2016.11.024 10.3171/2018.7.GKS181589 10.1227/NEU.0b013e31821bc44e 10.1530/EJE-17-0041 10.21037/gs-20-690 10.1023/B:PITU.0000004798.27230.ed 10.3171/2010.8.GKS10959 10.1007/s12020-020-02260-1 10.3171/jns.2002.97.supplement_5.0415
Journal of Neuro-oncology; Ironside N, Snyder H et. al.
Apr 25th, 2022 - Delayed hypopituitarism is the most common complication after stereotactic radiosurgery (SRS) for pituitary adenomas. The aim of this study was to investigate the relationship between the distance from the hypothalamic-pituitary axis to the treatm...
https://emedicine.medscape.com/article/923789-print
Apr 21st, 2022 - Practice Essentials The pituitary gland is called the master endocrine gland of the body because it controls the function of other endocrine organs. The anterior pituitary produces the hormones thyrotropin (thyroid-stimulating hormone [TSH]), cort...
https://doi.org/10.1507/endocrj.EJ21-0790
Endocrine Journal; Pekic S, Stojanovic M et. al.
Apr 12th, 2022 - Hematological neoplastic mass lesions of the sellar region are rare. We identified five cases of hematological malignancy with first presentation in the sellar region from our departmental database of 1,405 patients (0.36%) with sellar lesions dia...
Guidelines 5 results
https://doi.org/10.1507/endocrj.EJ19-0163
Endocrine Journal; Arima H, Iwama S et. al.
Jun 28th, 2019 - Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve,...
https://doi.org/10.1210/jc.2016-2118
The Journal of Clinical Endocrinology and Metabolism; Fleseriu M, Hashim IA et. al.
Nov 5th, 2016 - To formulate clinical practice guidelines for hormonal replacement in hypopituitarism in adults. The participants include an Endocrine Society-appointed Task Force of six experts, a methodologist, and a medical writer. The American Association for...
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.
Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...
https://doi.org/10.1227/NEU.0000000000001389
Neurosurgery Lucas JW, Bodach ME et. al.
Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present clinically with vision loss and hypopituitarism. To characterize the existing literature as it pertains to the initial management of NFPAs. A sys...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393422
The Journal of Clinical Endocrinology and Metabolism; Freda PU, Beckers AM et. al.
Apr 9th, 2011 - The aim was to formulate practice guidelines for endocrine evaluation and treatment of pituitary incidentalomas. Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails and one in-per...
Drugs 1 results see all →
Clinicaltrials.gov 17 results
https://clinicaltrials.gov/ct2/show/NCT05319301
Apr 8th, 2022 - Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated wi...
https://clinicaltrials.gov/ct2/show/NCT05206149
Jan 25th, 2022 - The diagnosis of secondary hypoadrenalism and GH deficiency (GHD) often requires the performance of a dynamic test. The glucagon stimulation test (GST) is one of the options for evaluating hypothalamic-pituitary function, representing a stimulus f...
https://clinicaltrials.gov/ct2/show/NCT03951818
Feb 18th, 2021 - Patient with thalassemia major have many endocrine diseases, such as hypopituitarism, hypothyroidism, hypoparathyroidis, osteoporosis, and etc.. These problems may be due to anemia itself or related to iron deposition. This study aimed to investig...
https://clinicaltrials.gov/ct2/show/NCT00507104
Dec 14th, 2020 - Recent data have demonstrated that hypopituitarism seems to be a frequent finding after traumatic brain injury (TBI) and/or subarachnoid hemorrhage (SAH). However, most of these studies referred to retrospective evaluations. There are only few pro...
https://clinicaltrials.gov/ct2/show/NCT00182091
Sep 2nd, 2020 - The aim of the study is to evaluate the effects of physiologic growth hormone (GH) replacement on cardiovascular risk markers, cardiac autonomic function, arterial distensibility, body composition, and quality of life in men and women with GH defi...
News 43 results
https://www.onclive.com/view/multidisciplinary-care-for-malignant-melanoma
Apr 2nd, 2021 - For High-Definition, Click The treatment of patients with metastatic melanoma requires a team approach. The complexities of this disease warrants impute from several specialists to properly deliver care, the panelists agree. Along these lines, h...
https://www.onclive.com/view/i-o-second-line-treatment
Apr 2nd, 2021 - Peter Galle, MD: What do we have as evidence? The only I/O agent that has been convincing in demonstrating benefit was atezolizumab in combination with bevacizumab in first line. That’s what we have. The monotherapy has not made it into a signific...
https://www.onclive.com/view/fda-approves-two-new-indications-for-pembrolizumab-in-advanced-melanoma
Dec 4th, 2020 - Roger M. Perlmutter, MD, PhD The FDA has expanded the approval for single-agent pembrolizumab (Keytruda) to include the frontline treatment of patients with advanced melanoma regardless of BRAF status, based on a substantial improvement in progre...
https://reference.medscape.com/viewarticle/875763_6
Sep 16th, 2020 - Answer 5/5 Which of the following is accurate regarding treatment of acromegaly? Your peers chose: Pharmacologic therapy is the first-line treatment for acromegaly 0% Radiation therapy is routinely indicated for most patients with acromegaly 0% Fo...
https://www.medpagetoday.com/endocrinology/generalendocrinology/85879
Apr 9th, 2020 - In response to the COVID-19 pandemic, endocrinologists should take certain precautions with patients they commonly treat, according to new guidance from editors of The Journal of Clinical Endocrinology & Metabolism. Editor-in-Chief Paul Stewart, M...